278 related articles for article (PubMed ID: 26134527)
1. Incidence and Burden of the Myelodysplastic Syndromes.
Cogle CR
Curr Hematol Malig Rep; 2015 Sep; 10(3):272-81. PubMed ID: 26134527
[TBL] [Abstract][Full Text] [Related]
2. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Cogle CR; Craig BM; Rollison DE; List AF
Blood; 2011 Jun; 117(26):7121-5. PubMed ID: 21531980
[TBL] [Abstract][Full Text] [Related]
3. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
[TBL] [Abstract][Full Text] [Related]
4. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
[TBL] [Abstract][Full Text] [Related]
5. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
6. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.
Cogle CR; Iannacone MR; Yu D; Cole AL; Imanirad I; Yan L; Mackinnon JA; List AF; Rollison DE
Leuk Res; 2014 Jan; 38(1):71-5. PubMed ID: 24280283
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Rollison DE; Howlader N; Smith MT; Strom SS; Merritt WD; Ries LA; Edwards BK; List AF
Blood; 2008 Jul; 112(1):45-52. PubMed ID: 18443215
[TBL] [Abstract][Full Text] [Related]
9. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Bonadies N; Feller A; Rovo A; Ruefer A; Blum S; Gerber B; Stuessi G; Benz R; Cantoni N; Holbro A; Schmidt A; Lehmann T; Wilk CM; Arndt V;
Cancer Epidemiol; 2017 Feb; 46():85-92. PubMed ID: 28056392
[TBL] [Abstract][Full Text] [Related]
10. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
11. Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.
McQuilten ZK; Wood EM; Polizzotto MN; Campbell LJ; Wall M; Curtis DJ; Farrugia H; McNeil JJ; Sundararajan V
Cancer; 2014 Jun; 120(11):1686-94. PubMed ID: 24643720
[TBL] [Abstract][Full Text] [Related]
12. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662
[TBL] [Abstract][Full Text] [Related]
13. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.
Goldberg SL; Chen E; Corral M; Guo A; Mody-Patel N; Pecora AL; Laouri M
J Clin Oncol; 2010 Jun; 28(17):2847-52. PubMed ID: 20421543
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany.
Gattermann N; Hofmann WK; Meessen A; Schmitz S; Tsamaloukas A; Vollmer T; Wedding U; Plesnila-Frank C; Schramm W; Berger K
Onkologie; 2008 Sep; 31(8-9):477-84. PubMed ID: 18787357
[TBL] [Abstract][Full Text] [Related]
16. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006.
De Roos AJ; Deeg HJ; Onstad L; Kopecky KJ; Bowles EJ; Yong M; Fryzek J; Davis S
Am J Hematol; 2010 Oct; 85(10):765-70. PubMed ID: 20815079
[TBL] [Abstract][Full Text] [Related]
17. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.
Rozema J; van Roon EN; Kibbelaar RE; Veeger NJGM; Slim CL; de Wit H; Hoogendoorn M;
Transfusion; 2021 Oct; 61(10):2877-2884. PubMed ID: 34480360
[TBL] [Abstract][Full Text] [Related]
18. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
Neukirchen J; Schoonen WM; Strupp C; Gattermann N; Aul C; Haas R; Germing U
Leuk Res; 2011 Dec; 35(12):1591-6. PubMed ID: 21708407
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: incidence and survival in the United States.
Ma X; Does M; Raza A; Mayne ST
Cancer; 2007 Apr; 109(8):1536-42. PubMed ID: 17345612
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
